TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by ...
- EMBARK for Clinical Trials (“EMBARK CT ”) being developed as a scalable model of psychedelic facilitation training to support future pivotal studies - - American Medical Association (“AMA”)’s new ...
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by ...
EMBARK has been described in a recent publication in the peer-reviewed journal Frontiers in Psychology. " There is a bottleneck of training in the field and a shortage of clinicians prepared to do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results